If you are weighing semaglutide vs tirzepatide, deciding between semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), the most useful thing to know is that there is no single "better" one for everyone, and we are not here to pick for you. These are two different GLP-1 medications that work in similar but not identical ways, and the right choice depends on your health history, your other medications, your insurance, and how your body responds. What we can do is lay the options side by side in plain language, attribute every number to the trial it came from, and help you walk into your prescriber's office with sharper questions. We sell nothing and recommend no specific drug. This is general information, not medical advice.
Semaglutide vs tirzepatide: the side-by-side at a glance
Here is the neutral head-to-head before you click anywhere. This is not a ranking, and neither column is the "winner." It is a quick orientation so the deeper page makes more sense.
| Semaglutide (Ozempic, Wegovy) | Tirzepatide (Mounjaro, Zepbound) | |
|---|---|---|
| How it acts | Single pathway: GLP-1 receptor only | Dual pathway: GIP and GLP-1 receptors |
| Side-effect family | Same GI profile: nausea, diarrhea, constipation, dose-related, worst while the dose is being raised | Same GI profile: nausea, diarrhea, constipation, dose-related, worst while the dose is being raised |
| Nausea figure you will see | About 44 percent (STEP and SUSTAIN trials) | About 25 to 33 percent (SURMOUNT and SURPASS trials) |
| The catch on those numbers | From separate trials, not head-to-head: different participants and different ways of asking, so they cannot cleanly say one causes more nausea than the other for you | From separate trials, not head-to-head: different participants and different ways of asking, so they cannot cleanly say one causes more nausea than the other for you |
Both are GLP-1 medications, so the everyday side effects overlap heavily. The clearest difference is mechanism, not comfort: tirzepatide acts on two gut-hormone pathways while semaglutide acts on one. The nausea percentages above come from separate trial programs, so treat them as a rough hint, not a verdict. For the careful breakdown, see semaglutide vs tirzepatide side effects.
What this section is for
A hub like this one is a map, not a verdict. Its whole job is to point you toward the deeper pages and to set expectations honestly before you get there.
A lot of what you read online about "semaglutide vs tirzepatide" is written by someone with a product to move or a clinic to fill. We are none of those. The Shot Guide is editorially independent and not affiliated with Novo Nordisk, Eli Lilly, or any manufacturer. So when we compare these medicines, the goal is not to crown a winner. It is to help you have a better, more specific conversation with the person who can actually prescribe and monitor your care.
The one comparison that gets searched most
The question almost everyone arrives with is some version of "which one has worse side effects." That is the right instinct, and it is the page we have built out in the most detail.
See semaglutide vs tirzepatide side effects for a careful side-by-side of what each medication tends to cause, how common those effects are, and how the timing of the rough patch compares. Both are GLP-1 medications, so the headline complaints overlap heavily: nausea, diarrhea, constipation, and other digestive effects that are dose-related, tend to be worst while your dose is being raised, and usually ease as your body settles in. For the broader map of those symptoms and what is normal, our side effects pillar is the place to start.
A number you will see everywhere, and why to be careful with it
You will run into figures like "nausea affected about 44 percent of people on semaglutide" and "around 25 to 33 percent on tirzepatide." Those numbers are real and they come from clinical trials, but there is a catch worth understanding before you lean on them.
They are cross-trial figures, not head-to-head. The semaglutide percentages come from one set of studies (the STEP and SUSTAIN trials) and the tirzepatide percentages from a different set (SURMOUNT and SURPASS), each run with different participants and different ways of asking about symptoms. Comparing them directly is a bit like comparing two students' grades from two different schools. It can hint at a pattern, but it cannot tell you cleanly that one medicine causes more nausea than the other for you. Where the evidence is that limited, we would rather say so than hand you a false certainty, and it is exactly the kind of nuance worth raising with your prescriber.
How we compare, and what we will not do
We lead with class and generic names (GLP-1 receptor agonist, semaglutide, tirzepatide) and use brand names only to help you recognize the medicine in your hand. We attribute every efficacy and safety figure to its named trial or FDA label. And we present the trade-offs plainly instead of declaring a champion, because the honest answer to "which is better" is almost always "it depends, and that is a conversation for you and your prescriber."
What we will not do: tell you which drug to take, give you dosing instructions, or steer you toward a particular product or pharmacy. Those decisions belong with the person managing your care, not with a website. Comparing options is useful right up until a real warning sign appears, and at that point comparison stops and getting help starts. If something feels wrong, skip the research and read when to get help now.
Questions people ask at 11pm
Is tirzepatide just a stronger version of semaglutide? Not exactly. Tirzepatide acts on two gut hormone pathways (GIP and GLP-1) while semaglutide acts on one, so they are genuinely different medications, not strengths of the same drug. Cross-trial data has hinted at larger average weight loss with tirzepatide, but because those studies were not run head-to-head, the cleanest answer is still "they differ, and your prescriber can say what that means for you."
Which one has fewer side effects? Both share the same family of digestive side effects, and the trial percentages come from separate studies that cannot be compared cleanly. There is no reliable "gentler" pick that holds for everyone. The honest move is to bring your specific history, like a sensitive stomach or other medications, to your prescriber.
Can I switch from one to the other if mine is rough? That is a real option some people and prescribers consider, but it is genuinely a medical decision, not a do-it-yourself one. Switching changes dosing, timing, and how your body adjusts. Please do not stop, start, or swap a medication on your own. Talk to your prescriber first.
How we reviewed this: this page draws on FDA labels and the named clinical trials for these medications (the STEP and SUSTAIN programs for semaglutide, the SURMOUNT and SURPASS programs for tirzepatide), with the trial percentages reported as cross-trial figures rather than head-to-head results. See our editorial and review policy and sourcing standards. Where the evidence cannot fairly compare two drugs, like direct head-to-head side-effect rates, we tell you that instead of pretending the numbers settle it.
Every medical claim above is cited to a primary source such as an FDA label, the NIH, or a named clinical trial. See how we review and our sourcing & fact-check standards.